The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

Novo Nordisk has launched the Childhood Obesity Prevention Initiative, aimed at combating rising obesity rates among children in underserved urban communities across six cities worldwide. Backed by an ...

Novo Nordisk has launched the Childhood Obesity Prevention Initiative, aimed at combating rising obesity rates among children ...

The initiative will launch in six cities across five continentsInterventions aim to increase physical activity and healthy ...

The global continuous glucose monitoring systems (CGMS) market was valued at approximately USD 6,626.6 million in 2021 and is expected to grow to USD 31,708.2 million by 2032, with a CAGR of 17.0% ...

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.

Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...

Activist investor Starboard Value acquired about $1 billion in Pfizer shares, seeking changes to improve performance. Former ...

The latest health news includes challenges faced by Gazan mothers in war-torn areas, U.S. bird flu vaccine expansions, ...

Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...